GSK press releases
Follow
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
